HOOKIPA Pharma Inc. announced that it has received U.S. Food and Drug Administration (FDA) acceptance of its Investigational New Drug (IND) application for HB-300, a novel arenaviral immunotherapy for the treatment of metastatic castration-resistant prostate cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9302 USD | +1.34% | +4.13% | +14.84% |
25/04 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
25/04 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.84% | 92.04M | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- Food and Drug Administration Accepts Hookipa’s Investigational New Drug Application for HB-300